No abstract available.
Drug Therapy* ; Osteoporosis*

Background: Osteoporosis in the elderly is now a pressing issue in the world as well as in Vietnam. Objective: To survey the proportion of osteoporosis in patients visited to the hospital, To search some factors related to the osteoporosis proportion in the elderly. Subjects and method: From April to June 2007, 344 patients aged 50 years or more visited to National Institute of Gerontology were surveyed, examined and measured the bone mineral density. This was a descriptive, cross-sectional study. Results: Osteoporosis proportions according to age were 28.2% at the age of 50 to 59 years; 42.85% at the age of 60 to 69 years; 66.6% at the age of 70 to 79 years and up to 100% at the age of over 80. The osteoporosis proportion in women increased substantially after menopause in comparison with men (45.5% compared to 33.1%). 50.9% of people working inactively and rarely done exercises had osteoporosis while this rate in people who had active work is 38.5%. After 10 years of menopause, there were 24.7% of people had osteoporosis and that number after 10 - 20 years was 52.7%, after more than 20 years was 61.9%. 50% of men with smoking had osteoporosis in comparison with 35.7% in non-smoking group. Conclusions: The proportion of osteoporosis increased with age. Acting regularly helped reduce osteoporosis. The longer the period of menopause was, the higher the rate of osteoporosis was. Using corticoid and smoking cigarettes increased the rate of osteoporosis.
Osteoporosis/ therapy ; Aged

No abstract available.
Animals ; Genetic Therapy* ; Mice* ; Osteoporosis*

Humans ; Medicine, Chinese Traditional ; Osteoporosis ; etiology ; therapy

Humans ; Osteoporosis ; drug therapy ; physiopathology ; surgery

OBJECTIVETo explore the effect of embedding thread at Shenshu (BL 23) on clinical pain of postmenopausal osteoporosis.

METHODSFifty-six cases were randomly divided into an embedding thread group, an embedding thread plus Leli group and a Leli group. The pain of the patient before treatment, 3 months and 6 months after treatment were assessed.

RESULTSThere was significant difference before and after treatment in the score of pain in both the embedding thread group and the embedding thread plus Leli group (P < 0.001), with no significant difference between the two groups (P > 0.05); there was no significant difference before and after treatment in the score of pain in the Leli group (P > 0.05), but with significant differences as compared with other two groups (both P < 0.001).

CONCLUSIONEmbedding thread at Shenshu (BL 23) has very obvious therapeutic effect on clinical pain of postmenopausal osteoporosis, and oral administration of Leli capsule has no significantly therapeutic effect on clinical pain of postmenopausal osteoporosis.

OBJECTIVE: To explore compounds, targets and mechanism of METHODS: The known effective Chinese herbal compound of YG pill was searched from traditional Chinese medicine integrated database(TCMID). Bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine (BATMAN-TCM) was used to predict target of components;DisGeNET and artificial literature reading were used to obtain targets of osteoporosis and bone remodeling;Cytoscape 3.7.1 software and its plug-ins BiN-GO and ClueGO were used to enrich the GO annotation and pathwaysof the related targets, and validation of the predicted target of YG pill were validated by 87 differentially expressed proteins in postmenopausal osteoporosis and postmenopausal osteoporosis disease models in postmenopausal patients with normal bone mass from the previous serum proteomics data. RESULTS: Totally 392 compounds were retrieved from YG pill, including 83 sovereign drugs (monkshood, cinnamon, deerhorn gelatin), 127 ministerial drugs (prepared rehmannia root, dogwood, wolfberry fruit and Chinese yam) and 182 supplementary drugs (cuscuta chinensis, eucommia ulmoides and Chinese angelica). Among them, there were 4 same compounds between sovereign drug and ministerial drug, 1 same compound between sovereign drug and supplementary drug, and 14 same compounds between ministerial drug and supplementary drug. Totally 2 112 trusted targets were identified, included 775 sovereign drugs, 1 483 ministerial drugs and 1 491 supplementary drugs;227 targets were selected from YG pill for treating osteoporosis, which participate in nearly 20 process of metabolic process, cell differentiation and biology, and data mining revealed that the process involved bone remodeling and bone mineralization. Acting site of cell mainly inclded 9 kinds of cell which had 13 molecular function. Results of KEGG metabolic pathway enrichment analysis showed 137 signal passages were obviously enriched. Among them, classical osteoclast differentiation signal passages and relative estrogen regulates signaling pathways of menopause were widely distributed in 27 signal passages. Sixtargets were screened by target validation, such as AGT, FGA, APOE, DKK3, P4HB and RAB7A. CONCLUSION The characteristics of multi-targets and multi-pathways of YG pill for the treatment of osteoporosis were clarified, which provided a clear direction for the in-depth research. The pharmacodynamic components of YG pill include 36 compounds, and their main action targets include FGA, AGT, APOE, DKK3, P4HB and RAB7A.
Drugs, Chinese Herbal ; Female ; Humans ; Medicine, Chinese Traditional ; Osteoporosis/drug therapy* ; Osteoporosis, Postmenopausal

Postmenopausal osteoporosis is a kind of degenerative disease, also described as "invisible killer." Estrogen is generally considered as the key hormone for women to maintain bone mineral content during their lives. Iron accumulation refers to a state of human serum ferritin that is higher than the normal value but less than 1000 μg/L. It has been found that iron accumulation and osteoporosis could occur simultaneously with the decrease in estrogen level after menopause. In recent years, many studies indicated that iron accumulation plays a vital role in postmenopausal osteoporosis, and a significant correlation has been found between iron accumulation and fragility fractures. In this review, we summarize and analyze the relevant literature including randomized controlled trials, systematic reviews, and meta-analyses between January 1996 and July 2022. We investigate the mechanism of the effect of iron accumulation on bone metabolism and discuss the relationship of iron accumulation, osteoporosis, and postmenopausal fragility fractures, as well as the main clinical treatment strategies. We conclude that it is necessary to pay attention to the phenomenon of iron accumulation in postmenopausal women with osteoporosis and explore the in-depth mechanism of abnormal bone metabolism caused by iron accumulation, in order to facilitate the discovery of effective therapeutic targets for postmenopausal osteoporosis.
Humans ; Female ; Osteoporotic Fractures ; Osteoporosis, Postmenopausal/drug therapy* ; Postmenopause ; Osteoporosis ; Bone Density ; Estrogens ; Iron/therapeutic use*

Treatments for osteoporosis have many varieties, and the role, characteristics of them are also different. This paper investigates from the perspective of physical therapy pulsed electromagnetic fields (PEMFs), shock wave, and low-intensity pulsed ultrasound (LIPUS) therapy. Then comprehensive analysis of their mechanism of action, clinical application of new advances for more reasonable choice for clinical treatment and further trend of research are discussed. Through the research and discussions, we find out the strengths, weaknesses, and the best method of treatment in order to achieve better therapeutic effect.
Combined Modality Therapy ; Electromagnetic Fields ; Humans ; Osteoporosis ; therapy ; Physical Therapy Modalities ; Ultrasonic Therapy

Both diabetes and osteoporosis are assuming epidemic proportions throughout the world. Accumulating data suggest that both types 1 and 2 diabetes are associated with an increased risk of fragility fractures. This increased risk appears to be largely independent of bone mineral density (BMD) which is most often noted to be low in type 1 diabetes and normal or increased in type 2 diabetes. This review explores the clinical characteristics of bone fragility in patients with diabetes and highlights studies that have evaluated BMD and fracture prediction tools in these patients. It also briefly reviews the current management principles of osteoporosis in diabetes, with special emphasis on the impact of diabetes medications on bone health as well as explores the efficacy of currently available antiosteoporosis pharmacotherapy in the diabetic population.
Bone Density ; Drug Therapy ; Humans ; Osteoporosis* ; Risk Assessment